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i(Yp) and emphasizes the importance of appropriate man-
agement of puberty in people with 45,X/46,X,i(Yp). Early hor-
mone treatment, concerns regarding fertility, emotional 
support, and a successful transition to adult care may help 
improve the physical and psychosocial well-being of affect-
ed patients.  © 2019  S. Karger AG, Basel 
 Gross structural abnormalities of the Y chromosome 
seem to occur less frequently than microdeletions. 
Among structural rearrangements of the Y chromosome, 
the isochromosome of Yp, i(Yp), appears to be the most 
uncommon; nevertheless, the real incidence of i(Yp) is 
unknown so far. Patients with gross deletions of Yq are 
reported as being affected by infertility and short stature 
[Bühler, 1980], but few persons are reported as patients 
affected by i(Yp). All these patients were described as 
males, infertile, or with ambiguous genitalia [Robinson 
et al., 1998].
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 Abstract 
 The Y-chromosome genes are primarily involved in sex de-
termination, stature control, spermatogenesis, and fertility. 
Among structural rearrangements of the Y chromosome, the 
isochromosome of Yp, i(Yp), appears to be the most uncom-
mon. We describe a detailed evolution of puberty in a boy 
with 45,X/46,X,i(Yp). Array CGH found 2 cell lines, one with 
i(Yp) and the other with monosomy X. Genetic analysis of 
currently known genes involved in Kallmann syndrome/nor-
mosomic central hypogonadotropic hypogonadism showed 
no abnormality. The patient presented with a pubertal 
course suggestive of a delayed puberty with gynecomastia, 
reduced growth rate, and infertility that need testosterone 
treatment to induce the appearance of the secondary sex 
characteristics. This patient shows the potential effects of 
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 The first person with i(Yp) with a description of tes-
ticular histology was reported in 2005. The patient was a 
27-year-old man with small testes affected by Sertoli-cell-
only syndrome because he had no germ cells in testicular 
tissue [Lin et al., 2005]. To our knowledge, only 10 pa-
tients with 45,X/46,X,i(Yp) mosaicism have been de-
scribed [Siebers et al., 1973; Moreira-Filho et al., 1979; 
Rary et al., 1979; Bühler, 1980; Hsu, 1994; Mckinlay Gard-
ner and Sutherland, 2003; Martinerie et al., 2012; Bertel-
loni et al., 2015], and no data were found regarding the 
course of puberty in these patients.
 Case Report 
 We report a 21-year-old male with right-sided gynecomastia 
since the age of 13. The patient’s past medical history was negative. 
His height was 151.4 cm (between the 25th and the 50th percentile 
on the growth charts of the Center for Disease Control (CDC) and 
Prevention [www.cdc.gov/growthcharts]) and his weight was 65.8 
kg (between the 90th and the 97th percentile, CDC charts). At the 
first physical examination, he had very sparse pubic hair, no axil-
lary hair, no facial hair, normal scalp hair, and a preadolescent 
voice. Pubertal development was at Tanner stage 1, with corre-
sponding prepubertal penis and scrotum size. The patient’s testi-
cles were bilaterally descended, and both had a volume of 1.5 mL 
and a normal consistency. The testicular descent was spontaneous 
during development. The patient showed no eunuchoid habitus 
and no dysmorphism. The patient’s target height was 177.5 cm (on 
the 50th percentile). Due to absent puberty, an accurate physical 
examination and biochemical/genetic analyses were performed. 
We also comment our results revising the so far reported literature 
in the field.
 Materials and Methods 
 Hormone Assays and Clinical Data 
 Serum FSH, LH, and testosterone were determined by immu-
nometric assay (Immulite 2000; Siemens, Erlangen, Germany) and 
serum inhibin B by ELISA (Active Inhibin B ELISA, Diagnostic 
Systems Laboratories, Webster, TX, USA). Sex hormone-binding 
globulin levels were measured using a solid-phase, chemilumines-
cent immunometric assay on Immulite 2000 (Medical Systems 
Corp., Genoa, Italy).
 Testicular volume was assessed using a standard Prader orchi-
dometer. Testicular and breast ultrasound scanning was per-
formed by an experienced radiologist. Smell testing was carried out 
using the Sniffin’ Sticks test.
 Genetic Analysis by Targeted Next-Generation Sequencing 
 The patient underwent a genetic investigation, using a targeted 
NGS technique, to search for rare allelic variants. We extracted the 
genomic DNA of the patient from peripheral blood lymphocytes 
using Gene Catcher gDNA 96 × 10 mL Automated Blood kit (In-
vitrogen, Life TechnologiesTM, Carlsbad, CA, USA). The  IHH 
gene panel was designed using Illumina Design Studio (San Diego, 
CA, USA) and included the following  IHH candidate genes: 
 ANOS1  ( KAL1 ),  FGFR1 ,  PROKR2 ,  PROK2 ,  GNRHR ,  GNRH1 , 
 GNRH2 ,  FGF8 ,  TAC3 , and  TACR3 . Libraries were prepared using 
Illumina Nextera Rapid Capture Custom Enrichment kits as previ-
ously described [Cangiano et al., 2019] and according to the man-
ufacturer’s protocols.
 FISH Analysis and Array CGH 
 Chromosomes were analyzed by GTG-banding. FISH analysis, 
with specific probes for the  SRY gene (LSI, Vysis), with centro-
meric probes of the Y chromosome (DYZ1, Vysis), and with probe 
KAL1 (Vysis), was carried out according to Pinkel et al. [1986], and 
an array CGH was done to detect genomic copy number variations 
at a higher resolution level of 40 kb (GenetiSure Pre-Screen Array 
Kit 4×180, Agilent).
Table 1.  Hormone values and sexual characteristics of our patient at different ages
Years LH, IU/L FSH, IU/L Testosterone, ng/mL Testicular 
volume, mL
Penis size (length × 
diameter), cm
Therapy, IM
13 <0.1 (1.5 – 9.3) 0.3 (0.7 – 11) <0.20 (2.62 – 15.93) 2 3.5 × 1 No
14 0.3 (1.5 – 9.3) 1.3 (0.7 – 11) <0.20 (2.62 – 15.93) 2.5 – 3 3.5 × 1 No
15 1.1 (1.5 – 9.3) 2.0 (0.7 – 11) 0.40 (2.62 – 15.93) 4 3.5 × 1 TE 50 mg, once 
every 28 days
16 7.3 (1.5 – 9.3) 7.4 (0.7 – 11) 0.68 (2.62 – 15.93) 4 7 × 2.5 TE 100 mg, once 
every 28 days
17 1 (1.5 – 9.3) 1.7 (0.7 – 11) 0.63 (2.62 – 15.93) 4 7.5 × 2.5 TE 100 mg, once 
every 28 days
18 <0.1 (1.5 – 9.3) <0.1 (0.7 – 11) 1.84 (2.62 – 15.93) 4 7 × 2.5 TE 100 mg, once 
every 21 days
18.25 4.18 (0.57 – 12.07) 2.14 (0.95-11.95) 3.47 (1.66 – 8.77) 4 7 × 2.5 No
20.5 4.08 (0.57 – 12.07) 6.6 (0.95-11.95) 2.90 (2.59 – 8.36) 5 7 × 2.5 No
20.75 2.03 (0.57 – 12.07) 6.8 (0.95-11.95) 2.49 (2.59 – 8.36) 7 7 × 2.5 No
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 Detection of Y Chromosome Microdeletions 
 The detection of Y-chromosome microdeletions was achieved 
by screening patients according to the European Academy of An-
drology guidelines [Krausz et al., 2014].
 Results 
 To investigate the patient’s gynecomastia, we initially 
evaluated the breast and scrotum ultrasonography and 
basal hormone profile. The scrotal ultrasonography re-
vealed a testicular longitudinal diameter of 18 mm for the 
right testis, and 17 mm for the left testis, corresponding 
to a bilateral volume of approximately 2 mL. The breast 
ultrasonography confirmed a unilateral gynecomastia of 
the right breast with a diameter of 3 cm.  Table 1 shows 
the hormonal values and sexual characteristics of our pa-
tient at different ages. A complete screening of the pitu-
itary functionality excluded other possible pituitary hor-
mone deficits, and inhibin B levels were 44.32 pg/mL 
(normal range 25–325 pg/mL).
 At the age of 14, the patient maintained a prepubertal 
stage of sexual development and relative short stature. 
The evaluation of the patient’s bone age resulted in a pre-
dicted adult height of 162.9 cm according to Bayley-Pin-
neau (below the 3rd percentile, CDC growth charts). The 
gonadotropin-releasing hormone stimulation test showed 
values of LH and FSH in the prepubertal range. The hu-
man chorionic gonadotropin stimulation test was nor-
mal. The patient reported a reduced sense of smell. We 
tested his olfactory capacity to evaluate a possible Kall-
mann syndrome. The test revealed a slight reduction in 
his ability to recognize nasal stimulants (11/16 tested 
odorants correctly recognized; reference range  ≥ 12). On 




























































the contrary, the taste examination was normal (total 
score: 14; reference range 9–16). The patient had a nor-
mal brain MRI scan of the pituitary-hypothalamic region 
and olfactory system, which finally ruled out lesions, 
masses, or other abnormalities suggestive of Kallmann 
syndrome. Standard karyotyping was also performed and 
detected an i(Yp) in the patient ( Fig. 1 ). FISH showed 2 
Yp signals, confirming the presence of an i(Yp). The lack 
of Yq was then confirmed by the inability to amplify any 
of the AZF loci by PCR with specific primers. FISH anal-
ysis using centromeric probes of the Y chromosome 
showed the signal, in both 100 metaphase cells and 200 
nuclei, and evidenced that the Y chromosome was mono-
centric. FISH specific for Kallmann syndrome did not re-
veal a microdeletion of the X chromosome in Xp22.3 and 
our genetic analysis for mutations in  ANOS1  ( KAL1 ), 
 FGFR1 ,  PROKR2 ,  PROK2 ,  GnRH1/2 ,  GnRHR ,  FGF8 , 
 TAC3 , and  TACR3 genes was negative. Therefore, the pa-
tient’s karyotype was 46,X,i(Yp).ishX(p22.3)(KAL1×1). 
The karyotype of both parents was normal.
 At the age of 15, because of absent puberty progres-
sion, the boy received intramuscular injections of testos-
terone enanthate (TE; Testoviron ® 100 mg) to induce 
sexual development and secondary sex characteristics. 
This therapy was started with a dose of 50 mg once every 
28 days. After 4 months of treatment, baseline serum TE 
levels were 1.51 ng/mL (reference range: 2.62–15.93 ng/
mL), so we increased the dose of TE to 100 mg once every 
21 days.
 In addition to the chromosomal anomaly, we hypoth-
esized that the patient could also be affected by isolated 
congenital hypogonadotropic hypogonadism (CHH), 
since, at the age of 17 and 6 months, he failed to enter pu-
berty in spite of the TE priming, and still presented with 
a prepubertal bilateral testicular volume <4 mL with low 
gonadotropins and absence of hypothalamic-pituitary le-
sions. The array CGH showed an amplification of the 
chromosomal region Yp.11.32q11.21 of about 14 Mb, 
containing approximately 40% mosaic cells and a dele-
tion of the region Yq11.21q12 of about 45 Mb, resulting 
in nullisomy. The result of the analysis, confirmed by mo-
lecular cytogenetics, performed on interphase nuclei un-
stimulated nuc ish (DYZ3 X0) [193/1000] and on inter-
phase nuclei stimulated nuc ish (DYZ3 X0) [96/1000], 
suggested that our patient had 2 cell lines, one with Yp 
and the other with monosomy X.
 No cardiac or renal abnormalities or stigmata of Turn-
er females have been suspected. The semen analysis per-
formed with valid erections at the age of 18 showed azo-
ospermia and normal viscosity and PH (7.2; normal 
range: 7.2–8) as well as a measured volume of 3.5 mL 
(normal WHO value >1.5 mL). At this stage, since spon-
taneous increase in gonadotropin levels occurred during 
androgen therapy, the HPG axis was revaluated at the age 
of 18 after discontinuing the androgen therapy. At that 
time, TE (3.47 ng/mL; normal ranges 1.66–8.77), inhibin 
B (295.16 pg/mL; normal range 25–325), LH (4.18 IU/L; 
normal range 0.57–12.07), and FSH (2.14 IU/L; normal 
range 0.95–11.95) levels were within normal range. At the 
age of 20, he still had normal hormonal levels (see  Ta-
ble 1 ), although total TE levels remained within low-nor-
mal reference range, with a penile length of 7 cm, small 
testes (5 mL), and mild gynecomastia. His final height was 
161 cm, which was 16.5 cm below the correct midparental 
height. Pubertal growth spurt was 9.6 cm. At the age of 
21, total TE was below the reference range, although cal-
culated free TE levels were normal (6.6 ng/mL, normal 
range >6.5), and the patient did not have specific symp-
toms of hypogonadism. He reported a normal libido with 
conserved spontaneous erection and no erectile dysfunc-
tion as well as normal concentration ability. Gonadotro-
pin levels were within the normal range.
 Discussion 
 We describe a 21-year-old man who came to our pedi-
atric clinic with persistent gynecomastia and pubertal de-
lay. He had a complex rearrangement involving the X and 
Y chromosomes, initially interpreted as an i(Yp) and sub-
sequently characterized as 45,X/46,X,i(Yp) mosaicism. 
To our knowledge, only 10 persons with 45,X/46,X,i(Yp) 
mosaicism have been described in the literature ( Table 2 ), 
and this is the first comprehensive evaluation of puberty 
in such a patient.
 Our patient should have 2 doses of Yp, and he did not 
show a 47,XYY phenotype or a Klinefelter syndrome phe-
notype [Kanakis and Nieschlag, 2018], only gynecomas-
tia. Karyotyping is not a routine investigation in patients 
with gynecomastia with the exception of those who pres-
ent with clinical features suggestive of Klinefelter syn-
drome [Bonomi  et al., 2017].
 On the contrary, the presence of persistent gyneco-
mastia associated with central hypogonadism in our pa-
tient prompted us to investigate his karyotype leading to 
a better characterization of the cytogenetic origin of his 
clinical symptoms and biochemical defect. Moreover, the 
discovery of this cytogenetic anomaly suggested us to rule 
out other underlying diseases and testicular tumors. The 
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including a dicentric Y chromosome has been estimated 
in about 26% [Verp and Simpson, 1987], and the develop-
ment of gynecomastia in these patients suggests possible 
malignant changes. Issa et al. [1998] reported a 33-year-
old male with i(Yp) in whom gynecomastia was the sole 
features of a testicular seminoma. Nevertheless, most cas-
es of gynecomastia are caused by a relative prevalence of 
estrogen action [Karmisholt et al., 2011] in the breast. The 
possible presence of testicular mass in the patient was 
ruled out, thus allowing us to conclude that the gyneco-
mastia was due to the peripheral aromatization of adrenal 
androgens. This was subsequently confirmed by gyneco-
mastia improvement following TE replacement therapy.
 Initially, the differential diagnosis was between consti-
tutional delay in growth and puberty and CHH [Har-
rington and Palmert, 2012; Palmert and Dunkel, 2012; 
Boehm et al., 2015; Bonomi et al, 2018]. The patient’s in-
hibin B levels were suggestive of CHH [Adan et al., 2010; 
Coutant et al., 2010]. As provided for by the internation-
al guidelines for CHH [Dunkel and Quinton, 2014; 
Boehm et al., 2015; Howard and Dunkel, 2018], our pa-
tient was initially treated with a long-acting testosterone 
ester (TE) with a good advance of secondary sexual devel-
opment, but there was no testicular growth in terms of 
volume, and basal/post-stimuli LH and FSH values were 
still in the prepubertal range. This lack of spontaneous 
testicular enlargement during the TE replacement thera-
py in our patient seems to confirm the presence of a fail-
ure in the hypothalamic-pituitary-gonadal (HPG) axis 
activation as in CHH in contrast to constitutional delay 
in growth and puberty [Boehm et al., 2015]. On the other 
hand, the lack of the Yq [Lindhardt Johansen et al., 2012] 
might also have played a major role in this respect. Nev-
ertheless, other aspects of the clinical picture of our pa-
tient also seem to suggest at least a partial misfunctioning 
of the HPG axis. Indeed, the patient showed recovery of 
the HPG axis functionality after a period of sexual steroid 
exposure as in the reversal form of CHH [Raivio et al., 
2007]. On the contrary, at the age of 21, the FSH levels 
were inappropriately normal despite a severe defective fi-
nal testicular volume, and the normal LH with a border-
line TE level might suggest a residual frailty of the HPG 
axis as in the reversal and relapse form of CHH [Sidhoum 
et al., 2014]. Nonetheless, no genetic allelic variants in the 
Table 2.  Eleven patients with 45,X/46,X,i(Yp) mosaicism
Reference 45,X cells Age, 
years







25/30, mitoses 24 20 mm, <–2.5 
SD at birth; 
30 mm, <–3 SD 
at 24 years
Perineal Abdominal/inguinal 
at birth; streak gonad/
seminoma at 23 years
Yes (years NA) NA IM, 24 years 152 cm, 
–3.8 SD
Hsu, 1994 25/30, mitoses 17 NA Scrotal Scrotal dysgenetic testis/
abdominal dysgenetic testis
Yes (14 years) 9.8/26 IU/L No 155.3 cm, 
3.2 SD
Bühler, 1980 1/3 of lympho-
cytes; 90% of 
left gonad cells
0 Phallus Scrotal Cryptorchidism (left) A feminizing opera-






19/30 mitoses Adult Male external 
genitalia








Rary et al., 
1979




Normal testis (right); 
 inguinal small testis (left)
NA NA No NA
Siebers et al., 
1973
12/50 mitoses 20 Female, exter-
nal genitalia





NA NA NA No NA NA NA NA NA
NA NA NA Yes Absence of germinal cells NA NA NA NA
Berteloni 
et al., 2015




Streak gonad (left) NA, GH therapy NA NA NA




Streak gonad (right) NA NA NA NA
Our patient 4/50 mitoses 21 Male, external 
genitalia
No NA No, gynecomastia 4.08/6.6 IU/L No 161 cm




























































major CHH candidate genes [Vezzoli et al., 2016] so far 
analyzed were identified, and no Y chromosomal genes, 
including those in Yq, are known to be involved in the 
HPG activation and/or functionality.
 The proband showed no physical signs of Ullrich-
Turner syndrome, except for a reduced growth rate. This 
raises the question why did our patient, carrying a dupli-
cation of the Yp and thus of the  SHOX gene, not have a 
tall stature. His stature and his loss of growth spurt may 
be the result of 3 opposing effects, i.e., duplication of the 
 SHOX  gene in i(Yp), haploinsufficiency of the  SHOX 
gene related to the 45,X cell, and deletion of the GCY lo-
cus in Y [Kirsch et al., 2004; Lin et al., 2005].
 Although the question of fertility preservation should 
arise in the context of adolescent pubertal disorders, this 
concern has not been frequently addressed in the pediat-
ric and adolescent literature. For the first time, we report 
the semen analysis in an adolescent with 45,X/46,X,i(Yp) 
that confirmed azoospermia. Even if we have no data on 
the gonadal histology of our patient, we have explained 
the azoospermia in the presence of normal FSH and in-
hibin B levels, assuming the presence of Sertoli-cell-
only syndrome at the end of his puberty. Secondly, 
45,X/46,X,i(Yp) formation results in duplication of the 
Yp pseudoautosomal region and deletion of Yq pseudo-
autosomal region, outcomes that may disrupt meiotic 
pairing of chromosomes X and Y and thereby preclude 
progression through meiosis. Finally, mitotic instabili-
ty and resultant X0 mosaicism in the germline may also 
contribute to spermatogenic defects [Lange et al., 2009; 
Krausz et al., 2011, 2014; Lindhardt Johansen et al., 2012].
 Conclusion 
 In summary, we report the first case of a boy with de-
layed puberty, gynecomastia, 45,X/46,X,i(Yp), and pos-
sible CHH. This report is offering several important take-
home messages for both clinicians and patients. First, 
chromosomal analysis allowed appropriate clinical deci-
sion, predicted the patient’s response to treatment, and 
permitted precise genetic counseling. Second, patients 
with 45,X/46,X,i(Yp) and delayed puberty require con-
stant clinical monitoring in order to verify the normal 
activation and functionality of the HPG axis. Third, the 
psychological benefit of achieving normal pubertal mile-
stones for all patients with 45,X/46,X,i(Yp) should not be 
underestimated. Early hormone therapy, concerns re-
garding fertility, emotional support, and a successful 
transition to adult care may help minimize negative im-
pacts on the physical and psychosocial well-being of pa-
tients with disrupted puberty.
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